A bord du TGV INOUI 6109 en direction de Marseille. Le conducteur apporte de la bonne humeur. C’est appréciable ! Un grand merci 🫶🤙SNCF Voyageurs

Come today between 5:30 & 7:30 PM (Halls G-H) and check our #Abstract No 1520 “Treatment of Adverse-Risk and Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients with FLAG-IDA ± Venetoclax and CLAG-M: A Monocentric Experience”. #ASH23 #SanDiego #Hematology

Looking forward to moderating a great line up of speakers in “604 - Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Therapeutic implications of LSCs and differentiation in myeloid malignancies” in Pacific Ballroom Salon 18-19! #ASH23 #AML #Leukemia #Hematology

#AI in #Hematology : Where do we stand in 2023? @ #ASH2023 #ASH23

Civilizations die because of gossip.

The classification of #AML with #CEBPA mutations has become more complicated with the #ICC and #WHO 2022 updates. 🧑‍⚕️Here are the results of 2 patients with AML and CEBPA mutations in my NGS series today.

The HARMONY APL project confirms that ATRA/ATO combination significantly improves outcome, regardless of patient age and Sanz risk score. ow.ly/3Jif50UCL0C #myeloidneoplasia #clinicaltrialsandobservations

Finally, I started reading The Three-Body Problem trilogy. 😌

Mutant p53 regulates a distinct gene set by a mode of genome occupancy that is shared with wild type | EMBO reports embopress.org/doi/full/10.10… James Manfredi, Ramy J. Rahmé and colleagues Icahn School of Medicine at Mount Sinai

The Mavs just traded Luka Doncic and you think you’re irreplaceable at work… 😂😅😅

“To effectively contain a civilization’s development and disarm it across such a long span of time, there is only one way: kill its science.” #The_Three_Body_Problem #Cixin_Liu

🩸 IDH1/2 mutations in intensively treated #AML: ➡️ NPM1 & DNMT3A co-mutations drive prognosis. ➡️ IDH1/2 persistence in remission does not predict progression. #leusm #AMLsm 🎉⁦Fenwarth Laurène⁩ nature.com/articles/s4140…

Vidéo d’info sur les syndromes myélodysplasiques en 2 minutes chrono⏱️ Merci Abbvie France pour cette opportunité

I’m glad to participate to the ESH meeting in Stockholm on the topic of “How I manage CAR-T therapies and bispecific antibodies in my patients” with non-Hodgkin lymphoma, myeloma & ALL. These not-so-novel-anymore therapies are part of our daily practice. #ESHCART2025

🧬 Among >17,000 NGS-screened patients, likely pathogenic #SH2B3 variants were enriched in suspected CMML (7.2%) and MPN (5.6%). When isolated, they were associated with ⬆️Hb and ⬆️platelets. nature.com/articles/s4140… #Hematology #Genomics #Myeloid

I’m glad to share with you our oral presentation at #ASH2025 meeting that will be presented on December 7, 2025: - Session Time: 9:30 AM - 11:00 AM
- Presentation Time: 10:30 AM - 10:45 AM
- Room: OCCC - Valencia Room W415BC